TransCode Therapeutics (RNAZ) Stock Price, News & Analysis

Company Overview

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: $4.87 to $5.20
• 50-Day Range: $4.98 to $9.18
• 52-Week Range: $3.82 to $20.99
• Volume: 20,547 shs
• Average Volume: 142,277 shs
• Market Capitalization: $4.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

TransCode Therapeutics Stock Analysis - MarketRank™

TransCode Therapeutics scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

TransCode Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

TransCode Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of TransCode Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TransCode Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

TransCode Therapeutics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.97% of the float of TransCode Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TransCode Therapeutics has a short interest ratio ("days to cover") of 1.87, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TransCode Therapeutics has recently decreased by 22.40%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TransCode Therapeutics does not currently pay a dividend.

Dividend Growth

TransCode Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.25

News Sentiment

TransCode Therapeutics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for TransCode Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for RNAZ on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added TransCode Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TransCode Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.10% of the stock of TransCode Therapeutics is held by insiders.

Percentage Held by Institutions

TransCode Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 6/09/2026
• AGM 2026: 7/02/2026
• Next Earnings (Estimated): 8/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RNAZ
• CIK: 1829635
• Web: www.transcodetherapeutics.com
• Phone: 857-837-3099
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($50.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.66 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -875.35%
• Return on Assets: -50.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.11
• Quick Ratio: 3.11

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.27 per share
• Price / Book: 0.44

Miscellaneous

• Outstanding Shares: 950,000
• Free Float: 949,000
• Market Cap: $4.73 million
• Optionable: Not Optionable
• Beta: 1.28